Literature DB >> 35812050

Risk factors and specific cancer types of second primary malignancies in patients with breast cancer receiving adjuvant radiotherapy: a case-control cohort study based on the SEER database.

Chuanxin Xia1, Lei Qin2, Yinzhi Wang2, Ling Yao1, Benchang Shia3,4, Szu-Yuan Wu3,4,5,6,7,8,9.   

Abstract

Patients with breast cancer can survive and live a long, cancer-free life; however, late complications of treatment, such as second primary malignancies (SPMs), have emerged as a competing cause of death and morbidity. We conducted a long-term population-based cohort study to identify the risk factors for SPMs and specific secondary cancer types after various latency periods of irradiated breast cancer. Cox proportional hazards regression was used to calculate the hazard ratio (HR) and 95% confidence interval (95% CI) for independent risk factors for SPM. We also calculated the HR of each specific cancer type and the latency time to specific SPMs. The risk of SPM was statistically significantly higher in patients with adjuvant RT than in patients without adjuvant RT (adjusted HR [aHR]: 1.105, 95% CI: 1.013-1.206). Compared with the control group, the case group had significantly increased risks of contralateral breast cancer (aHR: 1.268, 95% CI: 1.112-1.445), lung cancer (aHR: 1.218, 95% CI: 1.049-1.565), and urinary system cancer (aHR: 1.702, 95% CI: 1.140-2.543). Adjuvant RT for breast cancer increases the risk of SPM. Contralateral breast cancer, lung cancer, and bladder cancer were significant SPMs after breast RT, although the cumulative risk of SPM was low, at approximately 6, 10, and 13 cancers per 1000 women with irradiated breasts at latency periods of 5, 10, and 15 years, respectively, after breast RT. AJCR
Copyright © 2022.

Entities:  

Keywords:  Second primary malignancies; breast cancer; latency time; radiotherapy; risk factor

Year:  2022        PMID: 35812050      PMCID: PMC9251704     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   5.942


  57 in total

1.  Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma.

Authors:  Michael Schaapveld; Berthe M P Aleman; Anna M van Eggermond; Cécile P M Janus; Augustinus D G Krol; Richard W M van der Maazen; Judith Roesink; John M M Raemaekers; Jan Paul de Boer; Josée M Zijlstra; Gustaaf W van Imhoff; Eefke J Petersen; Philip M P Poortmans; Max Beijert; Marnix L Lybeert; Ina Mulder; Otto Visser; Marieke W J Louwman; Inge M Krul; Pieternella J Lugtenburg; Flora E van Leeuwen
Journal:  N Engl J Med       Date:  2015-12-24       Impact factor: 91.245

Review 2.  Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.

Authors:  Balazs I Bodai; Phillip Tuso
Journal:  Perm J       Date:  2015

Review 3.  Recent Developments in Radiation Oncology: An Overview of Individualised Treatment Strategies in Breast Cancer.

Authors:  Montserrat Pazos; Stephan Schönecker; Daniel Reitz; Paul Rogowski; Maximilian Niyazi; Filippo Alongi; Christiane Matuschek; Michael Braun; Nadia Harbeck; Claus Belka; Stefanie Corradini
Journal:  Breast Care (Basel)       Date:  2018-05-24       Impact factor: 2.860

4.  Radiation therapy and patient age in the survival from early-stage breast cancer.

Authors:  S A Joslyn
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-07-01       Impact factor: 7.038

5.  Sarcoma after radiation therapy: retrospective multiinstitutional study of 80 histologically confirmed cases. Radiation Therapist and Pathologist Groups of the Fédération Nationale des Centres de Lutte Contre le Cancer.

Authors:  J L Lagrange; A Ramaioli; M C Chateau; C Marchal; M Resbeut; P Richaud; P Lagarde; P Rambert; J Tortechaux; S H Seng; B de la Fontan; M Reme-Saumon; J Bof; J P Ghnassia; J M Coindre
Journal:  Radiology       Date:  2000-07       Impact factor: 11.105

6.  Increased risk of second cancers following breast cancer: role of the initial treatment.

Authors:  C Rubino; F de Vathaire; I Diallo; A Shamsaldin; M G Lê
Journal:  Breast Cancer Res Treat       Date:  2000-06       Impact factor: 4.872

7.  Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer.

Authors:  Maartje J Hooning; Berthe M P Aleman; Michael Hauptmann; Margreet H A Baaijens; Jan G M Klijn; Ruth Noyon; Marilyn Stovall; Flora E van Leeuwen
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

Review 8.  Tumour bed boost radiotherapy for women after breast-conserving surgery.

Authors:  Isabelle Kindts; Annouschka Laenen; Tom Depuydt; Caroline Weltens
Journal:  Cochrane Database Syst Rev       Date:  2017-11-06

9.  Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study.

Authors:  Michael Schaapveld; Otto Visser; Marieke J Louwman; Elisabeth G E de Vries; Pax H B Willemse; Renée Otter; Winette T A van der Graaf; Jan-Willem W Coebergh; Flora E van Leeuwen
Journal:  J Clin Oncol       Date:  2008-03-10       Impact factor: 44.544

10.  Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors.

Authors:  R Cooke; M E Jones; D Cunningham; S J Falk; D Gilson; B W Hancock; S J Harris; A Horwich; P J Hoskin; T Illidge; D C Linch; T A Lister; H H Lucraft; J A Radford; A M Stevens; I Syndikus; M V Williams; A J Swerdlow
Journal:  Br J Cancer       Date:  2013-05-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.